Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients with Osteoarthritis (OA) of the Knee
Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent ...
Monthly Prescribing Reference2d
Gene Therapy for Osteoarthritis Gets Fast Track Status
GNSC-001 is an investigational, adeno-associated virus gene therapy expressing an optimized form of IL-1Ra. The Food and Drug Administration (FDA) has granted Fast Track designation to GNSC-001 for ...